| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-084 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 公司于 2025 年 12 月 26 日召开第五届董事会第一次会议，审议通过了《关 于选举徐久振先生为公司第五届董事会董事长的议案》、《关于选举第五届董事会 专门委员会成员的议案》。全体董事一致同意选举徐久振先生担任公司第五届董 事会董事长，并选举产生了公司第五届董事会战略委员会、提名委员会、审计委 员会委员、薪酬与考核委员会委员，具体情况如下： | 董事会专门委员会 | 委员 | 召集人 | | --- | --- | --- | | 战略委员会 | 徐久振、王坤、吕顺辉 | 徐久振 | | 提名委员会 | 吕顺辉、孙佳、王坤 | 吕顺辉 | | 审计委员会 | 马如适、吕顺辉、金立印 | 马如适 | | 薪酬与考核委员会 | 孙佳、马如适、顾玮彧 | 孙佳 | 上海阿拉丁生化科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并 ...

上海阿拉丁生化科技股份有限公司（以下简称"公司"）第四届董事会任期 届满，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、 法规以及《公司章程》等有关规定，公司于 2025 年 12 月 26 日召开 2025 年第一 次职工代表大会，审议通过了《关于选举王坤女士为公司第五届董事会职工董事 的议案》，同意选举王坤女士为公司第五届董事会职工董事，职工董事简历详见 附件。 根据《公司章程》的规定，公司董事会设一名职工董事组成。本次职工代表 大会选举产生的职工董事，将与公司 2025 年第三次临时股东大会选举产生的董 事共同组成公司第五届董事会，任期自 2025 年第三次临时股东大会审议通过之 日起至公司第五届董事会任期届满为止。 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-085 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 董事会 上海阿拉丁生化科技股份有限公司 关于选举公司第五届董事会职工董事的公告 本公司董事会及全体董事保证公告内 ...

上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2025 年第三次临时股东大会的 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并参加了公司本次股东大会的全过程。本所保证本法律意见书所认定的事 实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导 性陈述或者重大遗漏，并愿意承担相应法律责任。 鉴此，本所律师根据上述法律、法规、规章及规范性文件的要求，按照律师 行业公认的业务标准、道德规范和勤勉尽责精神，现出具法律意见如下： 一、本次股东大会召集 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-083 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股东大会由公司董事会召集，董事长徐久振先生主持，会议采用现场投 票和网络投票相结合的表决方式。本次股东大会的召集和召开程序、出席会议人 员的资格和召集人资格、会议的表决程序和表决结果均符合《中华人民共和国公 司法》、《公司章程》及《股东大会议事规则》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 12 月 26 日 （二） 股东大会召开的地点：上海市浦东新区新金桥路 36 号南塔 16 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有 ...

Group 1 - The core viewpoint of the news is that Aladdin's stock has shown a modest increase, with a year-to-date rise of 13.47% and a market capitalization of 4.277 billion yuan as of December 24 [1] - Aladdin's main business involves the research, development, production, and sales of reagents, with a revenue composition of 96.96% from scientific reagents, 2.15% from laboratory consumables, and 0.89% from other sources [1] - The company is categorized under the Shenwan industry classification of basic chemicals - chemical products - other chemical products, and is associated with concepts such as small-cap, synthetic biology, monkeypox concept, ursodeoxycholic acid, and e-commerce [1] Group 2 - As of September 30, Aladdin reported a total revenue of 444 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 17.59%, while the net profit attributable to shareholders decreased by 20.41% to 57.76 million yuan [2] - The number of shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million yuan in dividends, with 150 million yuan distributed over the past three years [2]

公司代码：688179 公司简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 2025 年第三次临时股东大会 会议资料 中国·上海 2025 年 12 月 上海阿拉丁生化科技股份有限公司 2025 年第三次临时股东大会 上海阿拉丁生化科技股份有限公司 2025 年第三次临时股东大会 目录 | 2025 年第三次临时股东大会会议须知 3 | | --- | | 2025 年第三次临时股东大会会议议程 5 | | 2025 年第三次临时股东大会会议议案 7 | | 议案一：审议《关于取消监事会、调整董事会人数、变更注册资本及修订< | | 公司章程>并办理工商变更登记的议案》 7 | | 议案二：审议《关于制定或修订公司部分治理制度的议案》 9 | | 议案三：审议《关于修订<董事及高级管理人员薪酬管理制度>的议案》 .10 | | 议案四：审议《关于变更会计师事务所的议案》 11 | | 议案五：审议《关于公司 2025 年前三季度利润分配方案的议案》 12 | | 议案六：审议《关于公司董事会换届选举暨提名第五届董事会非独立董事候 | | 选人的议案》 13 | | 议 ...

Core Insights - The report highlights a significant shift in the pharmaceutical and biotechnology industry, moving from a follower to a leader in innovation, particularly in the context of international expansion and high-end product development [3][4] - The overall industry revenue and profit growth are expected to rebound after a period of decline, driven by the recovery of innovative drugs and the CXO sector [3][4] Industry Performance and Valuation Dynamics - In the first three quarters of 2025, the pharmaceutical sector experienced a notable divergence in performance across sub-sectors, with innovative drugs and CXO showing signs of recovery while others lagged [3][15] - The total revenue for 461 A-share listed companies in the pharmaceutical sector is projected to reach CNY 24,640 billion in 2024, with a slight decline of 0.7% year-on-year [15][18] - The overall valuation of the pharmaceutical sector remains low compared to historical averages, with innovative drugs benefiting from expectations of business development (BD) transactions [3][4][15] Innovative Drugs - The report emphasizes that the rapid development and lower costs of new drug development in China have positioned the country as a global leader, contributing approximately one-third of the global innovative R&D pipeline in 2025 [4][14] - The introduction of the commercial insurance innovative drug directory in 2025 is expected to stimulate payment growth for innovative drug products [3][4] CXO Sector - The CXO market is witnessing improved supply and demand dynamics, with CDMO companies entering a high-growth cycle due to strong demand for new molecular entities [4][15] - Key players in the CDMO space, such as WuXi AppTec, are highlighted for their robust project pipelines and market positioning [4][15] Life Sciences Upstream - The recovery in downstream demand is driving revenue growth in the life sciences sector, with companies actively pursuing mergers and acquisitions to expand their market presence [4][15] - Companies like Bide Pharmaceutical and Haoyuan Pharmaceutical are noted for their strong cash reserves and strategic acquisition activities [4][15] AI in Healthcare - The report discusses the impact of AI in healthcare, driven by government policies and the development of large-scale AI models, with companies like JD Health and Yimaitong being key players [4][5] High-End Medical Equipment - The high-end medical equipment sector is expected to benefit from a recovery in domestic procurement, import substitution, and accelerated international expansion [4][5] - Companies such as United Imaging and Kaili Medical are identified as potential beneficiaries of these trends [4][5] Orthopedic Consumables - The orthopedic market is expanding due to an aging population, with the negative impacts of centralized procurement clearing up, leading to a resurgence in demand for robotic-assisted surgeries [4][5] Traditional Chinese Medicine - Some traditional Chinese medicine companies are showing signs of revenue and profit improvement, driven by seasonal demand and adjustments in the essential medicine directory [4][5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Viewpoints - The recent performance of the pharmaceutical sector has been sluggish, with the innovative drug sector experiencing a significant rise in expectations earlier this year, now undergoing a correction. However, innovative medical devices are expected to benefit from ongoing government support for medical equipment upgrades and accelerated domestic replacement of high-end medical devices, alongside continuous expansion into overseas markets. A recovery is anticipated starting in Q3 2025, with performance gradually improving in 2026 [3][9]. - The high-end medical device sector is driven by the recovery of in-hospital procurement, suggesting a focus on companies such as United Imaging, Shandong Weigao, and Mindray Medical. The demand for consumer medical devices is gradually recovering, with a shift in market share from imported brands, indicating potential in companies like Kefu Medical and Yuyue Medical. The orthopedic consumables market has reached a price floor, with opportunities for market share growth in orthopedic robotics and overseas expansion, highlighting companies like Aikang Medical and Chuangli Medical [3][9]. - The pharmaceutical equipment sector is undergoing a cyclical recovery, with rapid overseas growth opening new avenues for growth. Domestic margins are expected to stabilize and profitability to improve, with a return to rational competition anticipated from late 2024. The recovery in innovative drug financing and frequent business development transactions are expected to drive a revival in contract manufacturing organizations (CMOs), positively impacting the pharmaceutical equipment industry. Additionally, global strategic safety backups and commitments from multinational pharmaceutical companies to invest in the U.S. market are projected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years, with a focus on companies like Senson International and Dongfulong [3][9]. - In the CXO and upstream life sciences supply chain, leading global CXO companies such as WuXi AppTec and Kanglong Huacheng are highlighted. Domestic clinical CRO leaders like Tigermed and Pruce are also recommended, along with resource-based CXOs such as Zhaoyan New Drug and Mediso. The upstream life sciences supply chain includes companies like Baipusais and Haier Biomedical [3][9]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's return was -1.04% last week, ranking 17th among 31 sub-industry indices. The medical services sub-sector had the highest weekly return at 1.67%, while the pharmaceutical commercial sub-sector had a return of -4.26% [3][9]. Industry Trends - The report emphasizes the ongoing low performance of the pharmaceutical sector, particularly in innovative drugs, while highlighting the potential recovery in innovative medical devices and the pharmaceutical equipment sector [3][9]. Recommendations - Specific companies to watch include United Imaging, Mindray Medical, Kefu Medical, and Aikang Medical in the high-end medical device sector, as well as Senson International and WuXi AppTec in the pharmaceutical equipment and CXO sectors [3][9].

Core Viewpoint - The establishment of the polysilicon storage platform "Guanghe Qiancheng" marks a significant shift in China's photovoltaic industry, moving from a fully market-driven competition phase to a new stage of "market operation + industry collaborative regulation" [1][7]. Group 1: Formation of the Storage Platform - The polysilicon storage platform "Guanghe Qiancheng" was officially registered on December 10, 2023, amidst the industry's overall "anti-involution" trend [1]. - The platform aims to eliminate excess capacity and settle accumulated debts within the industry [1]. Group 2: Shareholding Structure - "Guanghe Qiancheng" has a registered capital of 3 billion yuan, with shareholders comprising 10 photovoltaic and polysilicon companies [3]. - Major shareholders include Tongwei Co., Ltd. and GCL-Poly Energy Holdings, which together account for nearly 70% of the industry's effective polysilicon capacity [3][4]. Group 3: Pricing Mechanism Changes - The establishment of the storage platform is expected to fundamentally change the polysilicon pricing mechanism, with future sales prices including a "storage cost" [6]. - The mainstream price of polysilicon is projected to stabilize above 60,000 yuan per ton, marking a critical step towards industry value recovery and establishing a long-term healthy ecosystem [6][7]. Group 4: Market Reactions and Trends - Following the announcement of the storage platform, the capital market reacted with a decline in stock prices for major companies, including Tongwei and GCL-Poly [6]. - As of December 9, 2023, the spot price of polysilicon had risen nearly 50% from its low earlier in the year, reaching 52,000 yuan per ton [7].

证券日报网讯 12月10日晚间，阿拉丁发布公告称，2025年12月10日，公司第四届董事会第四十三次会 议审议通过了《关于公司 2025 年前三季度利润分配方案的议案》。 （文章来源：证券日报） ...